Anaplastic Large Cell Lymphoma - 340 Studies Found
Active, not recruiting |
: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas :
: |
Active, not recruiting |
: Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL :
|
Completed |
: Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma :
|
Active, not recruiting |
: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma :
|
Recruiting |
: Risk Stratification of Nodal PTCL :
: 2017-01-31 |
Recruiting |
: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) : Lymphoma : 2014-06-11 : Drug: Brentuximab Vedotin Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose |
Recruiting |
: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas : Non-Hodgkin Lymphoma : 2014-10-05 : Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b |
Available |
: A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 :
|
Active, not recruiting |
: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms :
|
Active, not recruiting |
: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma :
|